Enzalutamide

Type: Keyphrase
Name: Enzalutamide
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

East Coast Biotech Roundup: Amicus, Accelerator, Seventh Sense, & More

New York’s biotech scene is getting a jumpstart, and a Seattle startup incubator is getting a second wind in the process. One of biotech’s high fliers in 2014 soared once again. And one local biotech is awaiting some critical data that could make or break ... [Published Xconomy - Aug 15 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

What Do Humans and Laboratory Rats Have in Common?

Although narrow-entry, randomized, placebo-controlled trials based on preplanned deaths and overall survival may be the gold standard in the laboratory today, human beings are not laboratory rats. Sound scientific research can be done without lethality ... [Published The ASCO Post - Aug 15 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

PREVAIL Trial: Enzalutamide Before Chemotherapy Prolongs Survival in Metastatic Prostate Cancer

The androgen-receptor inhibitor enzalutamide (Xtandi) has been shown to prolong survival in men with metastatic castration-resistant prostate cancer with progressive disease after chemotherapy. In the phase III PREVAIL trial reported in The New England ... [Published The ASCO Post - Aug 15 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

Enzalutamide and the Landscape of Castration-Resistant Prostate Cancer: Integrating New Indications With Existing Agents

By Daniel P. Petrylak, MDAugust 15, 2014, Volume 5, Issue 13The androgen receptor axis is a validated target for the treatment of castration-resistant prostate cancer. Several perturbations in this pathway are postulated to lead to androgen-independent ... [Published The ASCO Post - Aug 15 2014]
First reported Aug 14 2014 - Updated Aug 14 2014 - 1 reports

Takeaways from the ASCO Annual Meeting from Gordon McVie

MDJ. GORDON MCVIE, MDImage ToolsAt this year's ASCO Annual Meeting, I was presented with a yellow ribbon that said “35 year member,” something that produced mixed feelings, but does give me the authority to say that this was a good ASCO! We've had some ... [Published Oncology Times - Aug 14 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

Tokai, Chasing the Field in Prostate Cancer, Files For IPO

Tokai Pharmaceuticals has been chasing after the big players in the prostate cancer field with the idea of combining some of the best features of their drugs into a single pill. Now, with that lead drug candidate, galeterone, on the precipice of a late-stage ... [Published Xconomy - Aug 12 2014]
First reported Aug 07 2014 - Updated Aug 08 2014 - 2 reports

Medivation's (MDVN) CEO David Hung on Q2 2014 Results - Earnings Call Transcript

OperatorGood afternoon, everyone, and welcome to Medivation's Second Quarter 2014 Financial Results Conference Call. This call is being recorded. [Operator Instructions] I would now like to turn the call over to Anne Bowdidge, Senior Director of Investor ... [Published Seeking Alpha - Aug 08 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

Cancer drug improves quality of life in men with incurable prostate cancer

The prostate cancer drug enzalutamide improves the quality of life of patients with advanced, incurable prostate cancer, as well as improving survival, a new study published in The Lancet Oncology shows.The study, of almost 900 men taking part in a major ... [Published Health Canal - Aug 07 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Prostate cancer The best fit for enzalutamide in metastatic prostate cancer

The PREVAIL trial compared enzalutamide and placebo in patients with metastatic castration-resistant prostate cancer who had not received prior chemotherapy, demonstrating an improvement in overall survival and other clinical, radiographic, and bioch ... [Published BioPortfolio - Jul 30 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

News NICE guidance on enzalutamide for metastatic hormonerelapsed prostate cancer

, the National Institute for Health and Care Excellence (NICE) recommended enzalutamide, within its marketing authorisation, for the treatment of metastatic hormone-relapsed prostate cancer that has progressed during or after docetaxe...Related Biotechnology, ... [Published BioPortfolio - Jul 24 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 5 reports

NICE Approves Xtandi and Yervoy

Cost regulators for the National Health Service in England and Wales have this morning issued guidance recommending the use of Bristol-Myers Squibb's Yervoy (ipilimumab) for skin cancer and Astellas' Xtandi (enzalutamide) for prostate cancer.First-line ... [Published American Journal of Managed Care - Jul 23 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

NHS limits use of life-extending prostate cancer drug

Enzalutamide will not be given to men who have already received another new treatmentThousands of men with advanced prostate cancer are to miss out on a life-extending drug because of new NHS restrictions, it has been reported.Enzalutamide prolongs life ... [Published Health Insurance Daily - Jul 23 2014]

Quotes

Dr. Zukiwski added, "We believe that Arno is the leader in the development of anti-progestins for the treatment of cancer, and that onapristone is the logical and viable next step in the evolution of anti-cancer hormone therapies. Our team is working diligently to position Arno for maximum long-term success and value creation for our stakeholders, and to capitalize on our recent progress with a goal of moving onapristone into Phase II clinical trials."
Graeme Woodside, Chief Executive Officer of the Prostate Cancer Foundation of New Zealand says, "New Zealand has significant disparities in survival for Māori men living with prostate cancer. As a community, it is absolutely critical we support and empower clinicians and Māori men themselves to actively manage their health and seek early diagnosis of prostate cancer in order to reduce the mortality rate"
...of the indicated patient population in the U S ," said Joseph Germino , M D , Vice President of Medical Affairs, Oncology, Bayer HealthCare. "We will continue to work with unlicensed sites to secure authorization to administer Xofigo, ensuring all patients who may benefit from this treatment have access. We are proud to reach this milestone and extend our appreciation to all providers of Xofigo for their hard work and ceaseless dedication to their patients who need this therapy."
...XTANDI for patients with mCRPC who have previously received docetaxel," said David Hung, M D , president and chief executive officer of Medivation. "As we approach our September 18 PDUFA date, we are prepared for the potential approval and subsequent launch of XTANDI in an expanded mCRPC indication, and we are excited about the opportunity for XTANDI to benefit more patients."

More Content

All (132) | News (100) | Reports (0) | Blogs (30) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Targeting the Androgen Receptor Signaling Axis ... [Published Cancernetwork.com - Aug 15 2014]
The Urology Perspective on Expanding Androgen-T... [Published Cancernetwork.com - Aug 15 2014]
Small Steps That Lead to a Giant Leap for Prost... [Published Cancernetwork.com - Aug 15 2014]
East Coast Biotech Roundup: Amicus, Accelerator... [Published Xconomy - Aug 15 2014]
What Do Humans and Laboratory Rats Have in Common? [Published The ASCO Post - Aug 15 2014]
Enzalutamide and the Landscape of Castration-Re... [Published The ASCO Post - Aug 15 2014]
PREVAIL Trial: Enzalutamide Before Chemotherapy... [Published The ASCO Post - Aug 15 2014]
Arno Therapeutics Reports Second Quarter 2014 F... [Published Town Hall - Aug 14 2014]
Takeaways from the ASCO Annual Meeting from Gor... [Published Oncology Times - Aug 14 2014]
Māori men at 70% increased risk of dying of pro... [Published Scoop - Aug 14 2014]
Maori men at 70% increased risk of dying of pro... [Published Yahoo!Xtra - Aug 14 2014]
Over 1,000 Medical Sites in the United States N... [Published Wall Street Business Network - Aug 13 2014]
Tokai, Chasing the Field in Prostate Cancer, Fi... [Published Xconomy - Aug 12 2014]
Medivation's (MDVN) CEO David Hung on Q2 2014 R... [Published Seeking Alpha - Aug 08 2014]
Medivation Reports Second Quarter Financial Res... [Published Pettinga Financial Advisors - Aug 07 2014]
Childhood brain tumours: breakthrough could spe... [Published Health Canal - Aug 07 2014]
Getting to the heart of why cancer survivors ar... [Published Health Canal - Aug 07 2014]
Cancer drug improves quality of life in men wit... [Published Health Canal - Aug 07 2014]
Blood and Saliva Tests Help Predict Return of H... [Published Health Canal - Aug 07 2014]
Astellas Pharma EMEA Announces New Senior Appoi... [Published OSIX News - Aug 07 2014]
Corcept Therapeutics' (CORT) CEO Joseph Belanof... [Published Seeking Alpha - Aug 06 2014]
One Drug To Rule Them All: Medivation's Xtandi ... [Published Seeking Alpha - Aug 05 2014]
John Fitzpatrick [Published Irish Independent - Aug 03 2014]
Astellas Pharma's (ALPMF) Q2 2014 Results - Ear... [Published Seeking Alpha - Aug 01 2014]
Rapid PSA Decline and Resistance to Abiraterone... [Published General Medicine eJournal - Aug 01 2014]
Androgen metabolism in prostate cancer: From mo... [Published UroToday - Aug 01 2014]
Prostate Cancer Foundation Announces 2014 Movem... [Published CBS Detroit - Jul 31 2014]
The Galien Foundation Announces 2014 Prix Galie... [Published TickerTech.com - Jul 31 2014]
Prostate cancer The best fit for enzalutamide i... [Published BioPortfolio - Jul 30 2014]
Two Cancer Drugs from Astellas, BMS Win NICE Re... [Published FDA News - Jul 28 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Enzalutamide in Metastatic Prostate Cancer befo... [Published NEJM Articles Most Widely Covered in the Press - Jun 10 2014]
Prostate cancer is the most commonly diagnosed cancer and the sixth leading cause of cancer-related death among men worldwide.1 Strategies to block androgen-receptor signaling have formed the backbone of prostate-cancer therapy since the first description ...
Enzalutamide in Metastatic Prostate Cancer befo... [Published NEJM Most Viewed Articles - Week - Jun 04 2014]
Enzalutamide in Metastatic Prostate Cancer befo... [Published NEJM Most Emailed Articles - Jun 04 2014]
New Drug May Boost Survival for Advanced Prosta... [Published MedlinePlus Health News - Jun 02 2014]
Enzalutamide also delays need for chemotherapy, researchers report Source: HealthDayRelated MedlinePlus Pages: Medicines , Prostate Cancer ...
New England Journal of Medicine Publishes Resul... [Published PR Newswire: Entertainment & Media - Jun 01 2014]
NORTHBROOK, Ill. and SAN FRANCISCO, JUNE 1, 2014 /PRNewswire/ -- Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc. (Nasdaq: MDVN) today announced the online publication in the New England ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
Astellas Announces Marketing Approval in Japan ... [Published Financial Services - Mar 24 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.